Cargando…
Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
PURPOSE: Examine the use of systemic phosphodiesterase inhibition (sildenafil) to clear central serous chorioretinopathy (CSCR). OBSERVATIONS: In a long-standing CSCR patient, sildenafil produced a rapid resolution. When discontinued (dechallenge) the CSCR returned. When rechallenged, the CSCR again...
Autores principales: | Coleman, D. Jackson, Lee, Winston, Daly, Suzanne, Breazzano, Mark P., Sparrow, Janet, Tsang, Stephen H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750488/ https://www.ncbi.nlm.nih.gov/pubmed/33364520 http://dx.doi.org/10.1016/j.ajoc.2020.100998 |
Ejemplares similares
-
Central serous chorioretinopathy following ingestion of sildenafil citrate
por: Mohammadpour, Mehrdad, et al.
Publicado: (2019) -
New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil
por: Cruz-Burgos, Marian, et al.
Publicado: (2021) -
Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
por: Kayık, Gülru, et al.
Publicado: (2017) -
Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques
por: Rutten, K., et al.
Publicado: (2007) -
Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)